There are targeted drugs for the treatment of rectal cancer. Targeted drugs for rectal cancer can be divided into three main categories, one is drugs targeting epidermal growth factor, such as cetuximab, the second is drugs inhibiting vascular endothelial growth factor receptor, such as bevacizumab, and the third is immune drugs, such as PD-L1 drugs. 1. Cetuximab: this drug can be combined with irinotecan for the treatment of EGFR-positive metastatic colorectal cancer after failure of irinotecan-based chemotherapy; combined with platinum platinum-based chemotherapeutic agents and fluorouracil for the first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck. 2. Bevacizumab: this drug is suitable for metastatic colorectal cancer, combined with 5-fluorouracil-based chemotherapy is suitable for the treatment of metastatic colorectal cancer patients. Patients are advised to go to regular hospitals and use the medicine under the guidance of professional doctors.